// App-Quantinova.ai

[OP0028] : EFFECTS OF SARILUMAB PLUS MTX ON CLINICAL, RADIOGRAPHIC, AND FUNCTIONAL ENDPOINTS IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: RESULTS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY

Researchers

Presenter

  • M. Genovese

Principal Investigators

  • R. M. Fleischmann

  • A. J. Kivitz

  • N. Graham

  • N. Stahl

  • G. Yancopoulos

  • T. W. Huizinga

  • D. van der Heijde

  • M. Rell-Bakalarska

  • R. Martincova

  • S. Fiore

  • P. Rohane

  • H. van Hoogstraten

  • C. Fan

  • J. van Adelsberg

  • S. Weinstein

Medical Centers

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Altoona Center for Clinical Research, Altoona Center for Clinical Research, Duncansville, United States

  • Rheumatology and Osteoporosis Outpatient Clinic, Rheumatology and Osteoporosis Outpatient Clinic, Warsaw, Poland

Locations

  • United States

  • Poland

  • Netherlands

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • High sensitivity C-reactive protein

  • Interleukin 6

Drug/Treatment

  • Methotrexate

  • Sarilumab

  • N-1197

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved